A Clinical Study of AK115 in Healthy Subjects

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

COMPLETED

Clinical Phase

PHASE1

Total Enrollment

42 participants

Study Classification

INTERVENTIONAL

Study Start Date

2022-03-18

Study Completion Date

2022-09-28

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This trial is a randomized, double-blind, placebo-controlled dose escalation phase I trial following single dose subcutaneous administration of AK115 injection.

It aims to evaluate the safety, pharmacokinetic characteristics, pharmacodynamic effect and immunogenicity of single dose of AK115 injection in healthy subjects.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

A Clinical Study of AK139 in Healthy Subjects

NCT06947109

Healthy Subjects

NOT_YET_RECRUITING PHASE1

A Clinical Study of AK0610

NCT06996704

Healthy Volunteer Study

RECRUITING PHASE1

A Study of AK3280 in Chinese Healthy Volunteers

NCT04926116

Healthy

COMPLETED PHASE1

A Phase I Clinical Study of a Single Dose of KLA480

NCT07030790

Healthy Participants

RECRUITING PHASE1

Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of ACZ885 in Healthy Japanese Male Volunteers

NCT00421226

Healthy

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Healthy Volunteers

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

SEQUENTIAL

Primary Study Purpose

TREATMENT

Blinding Strategy

QUADRUPLE

Participants Caregivers Investigators Outcome Assessors

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

AK115

Abdominal subcutaneous injection

Intervention Type DRUG

Placebo

Abdominal subcutaneous injection

Intervention Type DRUG

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

1. The subjects fully understand the purpose, content, process and possible adverse reactions of the trial, voluntarily participate in the trial, and sign the informed consent before any test procedure;
2. Healthy male and female subjects aged 18-55 years (including 18 and 55 years);
3. Male weight ≥ 50.0kg, female weight ≥ 45.0kg; Body mass index (BMI) = body weight (kg) / height 2 (M2), in the range of 19.0 \~ 26.0kg/m2 (including the critical value);
4. The blood pregnancy test results of female subjects of chidbearing potential during the screening period were negative. During the whole trial period and within 84 days after receiving the inveatigational drug, the subjects and their partners voluntarily take effective contraceptive measures specified in the protocol. Female subjects without childbearing potential need to meet the standards specified in the protocol,
5. The subjects can communicate well with the researchers, understand and comply with the requirements of this trial protocol.

Exclusion Criteria

1. Allergic to AK115 component and any monoclonal antibody, or have a history of allergies of 3 or more kinds food or drugs ;
2. There are accompanying diseases , or previous serious and chronic diseases and those who have not been cured;
3. The results of physical examination, laboratory examination or ECG examination in the screening period are judged by the researcher to be abnormal and clinically significant;
4. Have a history of transplantation of important organs;
5. Abnormal liver and kidney functions and blood routine, refer to the protocol
6. Hepatitis B surface antigen, hepatitis C antibody, HIV antigen antibody, Treponema pallidum antibody positive;
7. History of alcohol abuse or Drug abusers within 12 months before screening or those with positive urine drug screening results during screening;
8. Blood donation or massive blood loss (\> 400ml) or Smoking more than 5 cigarettes per day within 3 months before check-in;
9. Female subjects are in pregnancy or lactation;
10. Use of medications including over-the-counter medication within 14 days before the investigational drug;
11. Participated in the clinical trial of any trial drug within 3 months before the investigational drug or still within 5 half lives of other trial drugs (whichever is longer);
12. Subjects who received monoclonal antibodies or other biological agents within 3 months before investigational drug;
13. Subjects who had received systemic corticosteroids 12 months before screening;
14. Any conditions which, in the opinion of the Investigator, would make the subject unsuitable for enrollment

Minimum Eligible Age

18 Years

Maximum Eligible Age

55 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

Yes